NCT07866989Completed
Nebulized Verapamil in COPD Exacerbations
Effect of Nebulized Verapamil on Oxygenation in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Patients
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This clinical trial evaluated whether adding nebulized verapamil to conventional treatment could improve oxygenation and clinical status in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (COPD). A total of 60 participants were randomly assigned to two groups. One group received nebulized verapamil in addition to conventional treatment, while the other group received conventional treatment alone. Nebulized verapamil was given at a dose of 10 mg twice daily for three consecutive days. The study assessed changes in oxygenation, respiratory function, symptoms, functional status, and cardiovascular safety during the treatment period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 1 Oct 2026
- Start date
- 30 Apr 2023
- Primary completion date
- 30 Mar 2024
- Lead sponsor
- Ain Shams University
- Diseases
- COPD
- NCT number
- NCT07866989
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 30 Apr 2023 to the primary completion date, 30 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pre-existing cardiac disorders, including severe left ventricular dysfunction
- Arrhythmias
- Heart block
- Known hypersensitivity to verapamil
- Interstitial lung disease
- Lung cancer
Other
- Hypotension
- Bradycardia
- Requirement for mechanical ventilation
- Bronchiectasis
- Pneumonia
- Pulmonary embolism
Who the study is looking for
- Age older than 40 years
- Male or female
- Diagnosis of acute exacerbation of chronic obstructive pulmonary disease according to GOLD 2023 criteria
- With or without respiratory failure
- Left ventricular ejection fraction greater than 55%
- Right ventricular systolic pressure greater than 30 mmHg
Age in the registry: 41 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospitals Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.